Papers

Observational study of 353 applications to London multicentre research ethics committee 1997-2000

BMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7372.1081 (Published 09 November 2002) Cite this as: BMJ 2002;325:1081
  1. Malcolm Boyce (mboyce{at}hmrlondon.com), clinical director
  1. Hammersmith Medicines Research, Central Middlesex Hospital, London NW10 7NS
  • Accepted 15 May 2002

Since 1997 British studies involving five or more centres have required approval from both a multicentre research ethics committee1 and the local research ethics committee for each centre. A local committee can reject the protocol for local reasons but cannot amend it. Some researchers have criticised the process of obtaining ethical approval for multicentre studies,24 but little is known about the work of the 10 multicentre research ethics committees. I describe here the work of one of them.

Methods and results

I gathered and analysed data from the following documents sent to me as a member of London (formerly North Thames) multicentre research ethics committee before each monthly meeting during October 1997-November 2000: new applications, correspondence about continuing applications, list of recently approved applications, and minutes of previous meeting.

There were 353 new applications and 38 scheduled meetings. The median number of members at each meeting was 14 (range 11-16). Median numbers of new and continuing applications discussed at each meeting were 10 (range 3-14) and 4 (range 0-8) respectively. Of 353 new applications discussed at a first meeting, 14 (4%) were approved, 217 (62%) approved conditionally, 103 (29%) deferred, and 19 (5%) rejected and the researchers invited to resubmit. Deferred or rejected applications were reconsidered at up to four other meetings (table). Forty eight researchers whose applications were deferred or rejected were invited to attend the next meeting. 330 (93%) of 353 applications were eventually approved. Only one decision required a vote; others were made by consensus.

At some stage of the review process the committee conditionally approved 306 (87%) applications at scheduled meetings and delegated responsibility to the chairman and other members to resolve remaining queries.

Of 339 applications conditionally approved, deferred, or rejected at first meeting, 287 (85%) had queries about the patient information leaflet (such as inadequate information, jargon, poor clarity, need for proofreading) and 171 (50%) had queries about study design (such as use of placebo, stopping current treatment, choice of comparator drug). Rejected and deferred applications had proportionally more queries about study design, and also safety and statistics, than conditionally approved applications (see table on bmj.com).

I used correspondence for the 122 applications deferred or rejected at first meeting to calculate times taken to notify researchers and for them to respond: median times were 6 days (range 1-9) and 13 days (range 4-277), respectively.

Members were not given copies of approval letters to researchers so I could not calculate precise times from first meeting to approval. However, dates of meetings when an application was first considered and when members were informed of its approval were available for 266 applications. I took the difference as the best estimate of approval time. Median time was 64 days (range 7-386). Using the same method of calculation, median time from conditional approval to approval was 62 days (range 21-408).

Progress of all 353 applications

View this table:

Comment

Ethical review was often protracted, and few applications were approved unconditionally at first meeting. As expected, rejected or deferred applications had more profound queries than conditionally approved applications. Most patient information leaflets required changes, some extensive. More care and effort by researchers in preparing applications, particularly information leaflets,1 would shorten approval time.

The committee met its requirement of notifying researchers within 10 days of initial decision.1 But when the Clinical Trials Directive5 and governance arrangements for research ethics committees1 are implemented the committee will have to shorten the review process for continuing applications or reject more. The directive allows committees 60 days for a decision, and only one request for supplementary information (60 day period suspended until information received).

Acknowledgments

I thank Julie Wicks and Liz Clark for help with data collection, Professor Stacey, Central Office for Research Ethics Committees, and the chairman and members of London multicentre research ethics committee for agreeing to publication. My views are not necessarily theirs.

Footnotes

  • Funding None.

  • Competing interests I was principal researcher for one application, but took no part in the discussion and decision.

  • Embedded Image Details of queries raised appear on bmj.com

References

View Abstract